Finally, in Massó-Vallés et al. [141], the potential targeting of MYC, MYCN, and MYCL in lung cancer was discussed, emphasizing that a combination of MYC inhibitors with immunotherapies might represent a promising strategy for improving treatment outcomes, particularly given the role of MYC in immune suppression. Here, MYC is linked to lung carcinoma.